Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
7 GBX | -1.75% | -4.11% | -44.00% |
May. 21 | EARNINGS AND TRADING: Topps Tiles in strategic shift as swings to loss | AN |
May. 21 | Earnings Flash (IXI.L) IXICO Posts Fiscal H1 Revenue GBP2.5M | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company shows low valuation levels, with an enterprise value at 0.39 times its sales.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-44.00% | 4.38M | - | ||
+44.48% | 55.07B | B- | ||
-0.86% | 41.79B | B | ||
+44.19% | 40.22B | A | ||
-7.59% | 28.17B | C | ||
+12.30% | 26.28B | B- | ||
-21.83% | 18.93B | B | ||
+7.15% | 13.03B | B+ | ||
+29.40% | 12.26B | C+ | ||
+25.15% | 12.21B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- IXI Stock
- Ratings IXICO plc